Dimethyl Fumarate Capsule
Product Images NDC 68462-308

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dimethyl Fumarate (NDC 68462-308). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

120-14-bottle (120 14 Bottle)

Label for Dimethyl Fumarate Delayed-Release Capsules 120 mg by Glenmark Pharmaceuticals Inc., USA. The label indicates an oral capsule dosage form, with 14 capsules per container. It includes dosage instructions, storage information, the NDC number 68462-307-41, manufacturer details, and a barcode.*

FDA Label Image

240-60-bottle (240 60 Bottle)

Label for Dimethyl Fumarate Delayed-Release Capsules 240 mg by Glenmark Pharmaceuticals Inc., USA. The label indicates 60 capsules per package, oral route, prescription only, with instructions to swallow the capsule whole. Storage and dosage instructions are also included, along with the NDC code 68462-308-60 and barcode.*

FDA Label Image

30-day-starter-pack (30 Day Starter Pack)

Dimethyl Fumarate Delayed-Release Capsules 30-Day Starter Pack carton label showing two dosing options: 120 mg Starter Dose and 240 mg Regular Dose. The label indicates package contents with one bottle of 14 capsules of 120 mg and one bottle of 46 capsules of 240 mg. Manufactured for Glenmark Pharmaceuticals Inc., USA, the capsules are oral prescription drugs. Instructions for use and storage conditions are also noted.*

FDA Label Image

Figure_1 (Figure1)

A line graph showing the percentage of subjects with confirmed progression of disability over time (weeks) up to 96 weeks. The graph compares placebo (n=408) and Dimethyl Fumarate 240 mg BID (n=409) groups. The placebo group shows a higher progression percentage (27.1%) compared to the Dimethyl Fumarate group (16.4%) at study end. X-axis represents time on study in weeks; Y-axis represents the percentage of subjects with confirmed progression of disability.*

FDA Label Image

Glenmark-logo (Glenmark Logo)

FDA Label Image

Structural-formula (Structural Formula)

Chemical structure of dimethyl fumarate, depicting its molecular arrangement with two ester functional groups and a central double bond. The diagram features carbon (C), oxygen (O), and hydrogen (H) atoms connected to represent the chemical composition of the active ingredient dimethyl fumarate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.